Ivosenib 250MG (Ivosidenib)

Basic Product Information of Ivosenib (Ivosidenib) 250mg

How Ivosenib (Ivosidenib) Works

Ivosenib contains Ivosidenib, a small-molecule inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme. In certain cancers, mutations in the IDH1 gene cause the enzyme to produce abnormally high levels of an oncometabolite called 2-hydroxyglutarate (2-HG). Accumulated 2-HG interferes with normal cellular processes, blocking the healthy differentiation of blood-forming or tumour cells and contributing to the malignant, poorly differentiated state seen in IDH1-mutated cancers.

By inhibiting the mutant IDH1 enzyme, Ivosenib substantially reduces 2-HG levels, restoring more normal cellular differentiation. In clinical studies, repeated dosing of Ivosidenib reduced 2-HG concentrations in bone marrow to levels similar to those seen in healthy individuals, and produced a comparable reduction in tumour tissue from patients with cholangiocarcinoma.

Ivosenib is taken as a once-daily oral tablet, and treatment is only appropriate for patients whose cancer has been confirmed to carry a susceptible IDH1 mutation, using an approved diagnostic test.

Indications for Ivosenib (Ivosidenib)

Ivosenib (Ivosidenib) is indicated for patients with a susceptible IDH1 mutation, as detected by an approved test, for the following conditions:

Benefits of Ivosenib (Ivosidenib) 250mg

How to Take Ivosenib (Ivosidenib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Ivosenib treatment, particularly in the first weeks. Your oncology team will monitor closely for signs and symptoms of differentiation syndrome, including unexplained fever, breathlessness, rapid weight gain, or swelling. Monitoring also includes electrocardiograms (ECG) and electrolytes, given the risk of QTc interval prolongation, and periodic complete blood counts and liver function tests. Report any breathlessness, fever, rapid weight gain, swelling of the legs, dizziness, palpitations, or fainting to your oncology team immediately.

Drug Interactions and Important Information

Coadministration of Ivosenib with strong or moderate CYP3A4 inhibitors increases Ivosidenib plasma concentrations and the risk of QTc interval prolongation; alternative therapies that are not strong or moderate CYP3A4 inhibitors should be considered where possible, and a dose reduction is required if coadministration cannot be avoided, as detailed in the dosing section above. Coadministration with strong or moderate CYP3A4 inducers decreases Ivosidenib exposure and may reduce effectiveness; avoid where possible.

Avoid concomitant use of Ivosenib with other medicines known to prolong the QTc interval; if unavoidable, monitor patients closely for increased risk of QTc prolongation. Breastfeeding is not recommended during treatment. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Ivosenib.

Side Effects and Precautions

Who Should Use Ivosenib (Ivosidenib)?

Ivosenib is suitable for adult patients with IDH1-mutated newly diagnosed AML (aged 75 or older, or with comorbidities precluding intensive chemotherapy), IDH1-mutated relapsed or refractory AML or MDS, or IDH1-mutated previously treated cholangiocarcinoma, confirmed by an approved IDH1 mutation test. It is prescribed by haemato-oncologists and medical oncologists experienced in biomarker-guided cancer therapy and in recognising differentiation syndrome. A thorough medical assessment including IDH1 testing, baseline ECG and electrolytes, and blood counts is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Ivosenib under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Ivosenib is one of Everest’s specialty precision-oncology products, offering a bioequivalent alternative to Tibsovo by Servier Pharmaceuticals at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Ivosenib (Ivosidenib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Ivosenib (Ivosidenib) from Mediaid Pharmacy?

Ivosenib represents one of the most precise treatment options available for IDH1-mutated blood cancers and cholangiocarcinoma, targeting the exact metabolic driver behind the disease. As the generic equivalent of Tibsovo, it delivers the same active ingredient, Ivosidenib, with the same proven IDH1-inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Ivosenib gives patients worldwide access to precision-targeted cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Ivosidenib option with worldwide delivery, Ivosenib from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Ivosenib (Ivosidenib)